Bone and Mineral Metabolism Disorders News

A study of patients with chronic kidney disease showed no direct relationship between lower eGFR levels and metabolic rate, leading researchers to suggest other factors may play a bigger role in differences in energy metabolism.

The FDA has approved Alnylam Pharmaceuticals Inc.’s lumasiran, known as Oxlumo, for the treatment of primary hyperoxaluria type 1 in both adults and children.

Patients with heart failure and reduced ejection fraction who were randomized to dapagliflozin had half the risk of moderate to severe hyperkalemia vs. placebo, according to results of the DAPA-HF trial presented at ASN Kidney Week.

From 2008 to 2015, prescriptions for vitamin D sterols trended downward while prescriptions for phosphate binders and cinacalcet increased for patients with kidney failure at 359 facilities affiliated with Dialysis Clinic Inc.

Kidney disease guidelines paired with checklist and care coordination logs were linked to improved results in patients with mineral and bone disorders, according to a presentation.

Improved potassium levels impacted the physical and/or mental well-being of patients managing hyperkalemia, according to study results presented at the American Nephrology Nurses Association National Symposium.

In the course of 18 months, supplementation with cholecalciferol did not attenuate vascular calcification progression in patients with chronic kidney disease and vitamin D insufficiency, though it did restore 25-hydroxyvitamin D levels.

Ferric citrate may be more effective than ferrous sulfate for treating iron deficiency in patients with chronic kidney disease, according to this study.

A review of published studies revealed hip and nonvertebral fracture risks increased for patients with chronic kidney disease stages G3a-G5D, leading researchers to suggest CKD be considered as an additional risk factor for fractures.

Researchers found no difference in coronary artery calcification progression between patients with chronic kidney disease and secondary hyperparathyroidism who were randomized to either calcitriol or paricalcitol.